CINECA IRIS Institutional Research Information System

CONCA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.487
AS - Asia 1.401
EU - Europa 800
SA - Sud America 203
AF - Africa 79
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.977
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.436
SG - Singapore 526
IT - Italia 376
CN - Cina 320
HK - Hong Kong 224
BR - Brasile 163
VN - Vietnam 103
DE - Germania 90
SE - Svezia 60
GB - Regno Unito 54
FR - Francia 47
JP - Giappone 45
FI - Finlandia 35
CI - Costa d'Avorio 34
IN - India 34
KR - Corea 30
NL - Olanda 23
PL - Polonia 21
BD - Bangladesh 18
CA - Canada 18
RU - Federazione Russa 18
AR - Argentina 16
ID - Indonesia 16
AT - Austria 15
MX - Messico 15
BG - Bulgaria 13
TR - Turchia 13
PH - Filippine 10
UZ - Uzbekistan 10
ES - Italia 9
LT - Lituania 8
PK - Pakistan 8
IQ - Iraq 7
NG - Nigeria 7
ZA - Sudafrica 7
MA - Marocco 6
SN - Senegal 6
UA - Ucraina 6
VE - Venezuela 6
EC - Ecuador 5
NZ - Nuova Zelanda 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
EG - Egitto 4
IE - Irlanda 4
JO - Giordania 4
PE - Perù 4
BY - Bielorussia 3
CH - Svizzera 3
CL - Cile 3
CO - Colombia 3
HN - Honduras 3
KE - Kenya 3
KG - Kirghizistan 3
MY - Malesia 3
PA - Panama 3
SA - Arabia Saudita 3
TN - Tunisia 3
AM - Armenia 2
AZ - Azerbaigian 2
ET - Etiopia 2
GT - Guatemala 2
KZ - Kazakistan 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
TH - Thailandia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GD - Grenada 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MT - Malta 1
NO - Norvegia 1
PR - Porto Rico 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
Totale 3.973
Salva come PNG Salva come JPEG
Città #
Singapore 302
Ashburn 215
Hong Kong 213
San Jose 213
Santa Clara 155
Dallas 151
Los Angeles 78
Chandler 74
Shanghai 73
New York 51
Beijing 50
Florence 43
Boardman 40
Munich 40
Tokyo 39
Ho Chi Minh City 35
Abidjan 34
Hefei 32
Pisa 31
London 28
Seoul 26
Hanoi 23
Milan 21
Cascina 20
Genoa 20
Turin 18
Turku 18
Warsaw 18
Rome 17
São Paulo 17
Council Bluffs 16
Fairfield 15
Lauterbourg 15
Redondo Beach 15
Frankfurt am Main 14
Helsinki 13
Lawrence 13
Princeton 13
Sofia 13
Orem 12
Naples 11
Ogden 11
Bremen 10
Medford 10
Vienna 10
Fuzhou 9
Houston 9
Istanbul 9
Nuremberg 9
Tashkent 9
Buffalo 8
Gargallo 7
Lagos 7
Mumbai 7
Stockholm 7
Wilmington 7
Dakar 6
Denver 6
Düsseldorf 6
Poplar 6
Toronto 6
Auckland 5
Bari 5
Bexley 5
Chicago 5
Da Nang 5
Phoenix 5
Quanzhou 5
San Diego 5
Amman 4
Atlanta 4
Avaré 4
Biên Hòa 4
Cairo 4
Dhaka 4
Dublin 4
Haiphong 4
Jakarta 4
Kent 4
Ottawa 4
Pistoia 4
Porto Alegre 4
Qingdao 4
Tangerang 4
Verona 4
Adria 3
Amsterdam 3
Ann Arbor 3
Bishkek 3
Bologna 3
Brasília 3
Brooklyn 3
Campo Grande 3
Clifton 3
Coreglia Antelminelli 3
Guangzhou 3
Hyderabad 3
Johannesburg 3
Karachi 3
Lappeenranta 3
Totale 2.553
Salva come PNG Salva come JPEG
Nome #
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 190
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 181
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 167
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 165
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 149
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 132
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 128
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development 124
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 123
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 121
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 121
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 118
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers 115
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 112
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 111
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 110
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 103
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 103
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 102
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 102
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis 100
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 99
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 97
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 95
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 94
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer 87
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 84
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study 82
Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials 77
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden 75
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 72
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer 69
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 66
null 65
null 57
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 56
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 50
null 35
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 33
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study 30
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study 24
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment 20
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 15
null 15
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 13
Totale 4.087
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.807
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.807
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 10 1 12 10 1 7 13 5 18 34
2022/2023319 23 45 19 19 29 37 10 18 79 1 33 6
2023/2024409 16 29 53 41 30 48 54 13 17 25 44 39
2024/20251.345 59 41 19 62 108 140 114 67 148 127 169 291
2025/20261.903 161 212 173 159 224 131 272 125 111 191 131 13
Totale 4.087